The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 9 , ISSUE 3 ( March, 2008 ) > List of Articles

RESEARCH ARTICLE

Current Opinion on Drug-induced Oral Reactions: A Comprehensive Review

Mohammad Abdollahi, Mania Radfar, Roja Rahimi

Citation Information : Abdollahi M, Radfar M, Rahimi R. Current Opinion on Drug-induced Oral Reactions: A Comprehensive Review. J Contemp Dent Pract 2008; 9 (3):1-15.

DOI: 10.5005/jcdp-9-3-1

License: CC BY-NC 3.0

Published Online: 01-03-2008

Copyright Statement:  Copyright © 2008; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

The aim of this comprehensive review is to present an update to our previous review about drug-induced oral reactions. All drugs that may cause adverse effects in the mouth and related structures are reviewed.

Background

Every drug can produce untoward consequences even when used according to standard or recommended methods of administration. Adverse drug reactions can involve every organ and system of the body and are frequently mistaken for signs of underlying disease. The mouth and associated structures can also be affected by many drugs or chemicals. Good oral health including salivary function is very important in maintaining whole body health. Drug reactions can be categorized as to the parts of the oral complex such as the oral mucosa and tongue, periodontal tissues, dental structures, salivary glands, cleft lip and palate, muscles, and nerves.

Review Results

This review suggests the number of drugs and chemicals that can produce adverse or toxic reactions in the oral cavity are on the rise. An updated listing of offending drugs is provided along with current strategies for dealing with adverse reactions.

Conclusion

Clinicians must constantly update their knowledge of drugs used by their patients. Attention must be paid to their toxic and unwanted effects that in many cases may be similar to characteristics of common diseases.

Clinical Significance

Dentists and specialists of oral diseases should be aware of adverse drug oral reactions for better diagnosis of oral diseases, administration of drugs, and patient compliance during drug therapy.

Citation

Abdollahi M, Rahimi R, Radfar M. Current Opinion on Drug-induced Oral Reactions: A Comprehensive Review. J Contemp Dent Pract 2008 March; (9)3:001-015.


PDF Share
  1. Medications’ impact on oral health. J Am Dent Assoc. 2004 Oct;135(10):1440-8.
  2. Oral manifestations of drug therapy. Dent Clin North Am. 2002 Oct;46(4):857-68.
  3. Drugs and oral disorders. Periodontol 2000. 1998 Oct;18:21-36.
  4. Oral side-effects of the most frequently prescribed drugs. Spec Care Dentist 1994; 14(3):96-102.
  5. A review of drug-induced oral reactions. J Contemp Dent Pract 2003, 4(1):10-31.
  6. Chlorhexidine mouthwash-induced fixed drug eruption; case report and review of the literature. Oral Surg Oral Med Oral Pathol. 1991; 71(4):431-434.
  7. Fixed drug eruption due to ibuprofen. Allergol Immunopathol (Madr). 2006, 4(6):280-1.
  8. Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med. 2006, 30;355(22):e25.
  9. Mucosal disease series. Number VI. Recurrent aphthous stomatitis. Oral Dis 2006, 12(1):1-21.
  10. Clinical practice. Aphthous ulceration. N Engl J Med. 2006 Jul 13;355(2):165-72.
  11. Recurrent aphthous stomatitis: investigation of possible etiologic factors. Am J Otolaryngol. 2006, 27(4):229-32.
  12. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol 2005, 52(2 Suppl 1):35-7.
  13. Aphthous ulcers and imiquimod. J Am Acad Dermatol 2005, 53(2):360-1.
  14. Early onset of oral aphthous ulcers with weekly docetaxel. Neth J Med 2005, 63(9):364-6.
  15. Oral aphthous-like ulceration due to tiotropium bromide. Med Oral Patol Oral Cir Bucal 2007, 12(3):E209-10.
  16. Recurrent aphthous stomatitis. Dent Clin North Am 2005, 49(1):31-47.
  17. Burning mouth syndrome: etiology. Rev Bras Otorrinolaringol (Engl Ed) 2006, 72(3):419-23.
  18. Burning mouth syndrome (stomatodynia). QJM 2007, 100(8):527-30.
  19. Burning mouth syndrome: clinical presentation, diagnosis and treatment. Australas J Dermatol 2006, 47(2):77-81.
  20. Stomatodynia (burning mouth) as a complication of enalapril therapy. Oral Dis 2004, 10(4):244-5.
  21. Scalded mouth caused by angiotensin converting enzyme inhibitors. B M J 1982,284:1672-1673.
  22. Lisinopril-induced scalded mouth syndrome. Ann Pharmacother 1992,26:1381-1382.
  23. Scalded mouth syndrome caused by angiotensin converting enzyme inhibitors: two case reports. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997, 83(6):665-667.
  24. Burning mouth syndrome after taking clonazepam. Ann Pharmacother 2001, 35(7-8):874-876.
  25. A burning mouth associated with the use of hormone replacement therapy. J Br Menopause Soc 2005, 11(1):38.
  26. Burning mouth syndrome due to efavirenz therapy. Ann Pharmacother 2006, 40(7-8):1471-2.
  27. An up-to-date view on burning mouth syndrome. Minerva Stomatol 2007, 56(6):327-40.
  28. Drug eruption reference manual. London, The Parthenon Publishing Group, 2001: 274-421.
  29. 133.
  30. Drug-induced skin reactions. J Pharm Pract Res 2003, 33(1):12-15.
  31. Multidrug-induced erythema multiforme. J Investig Allergol Clin Immunol 2007, 17(3):196-8.
  32. Mucosal disease series. Number IV. Erythema multiforme. Oral Dis 2005, 11(5):261-7.
  33. Mouth ulcers of more serious connotation. Br Dent J 2005, 199:339–343.
  34. Ginseng as a cause for Stevens-Johnson syndrome? Lancet 1996, 347(9011):1344.
  35. Verapamil-associated Stevens-Johnson syndrome. DICP 1989, 23(12):987-988.
  36. Lamotrigine-induced Stevens-Johnson syndrome. Am J Health Syst Pharm 2007, 1;64(3):273-5.
  37. Oral medicine--update for the dental practitioner. Aphthous and other common ulcers. Br Dent J 2005, 10;199(5):259-64.
  38. Letter: Mouth ulceration and slow-release potassium tablets. Br Med J 1974, 19;4(5937):164-165.
  39. Tetracycline-induced oral mucosal ulcerations. Ann Pharmacother 1996, 30(5):547-548.
  40. Proguanil, chloroquine, and mouth ulcers. Lancet 1990, 335(8682):164.
  41. Oral mucosal ulceration from disopyramide. Ann Pharmacother 1995, 29(12):1299-1300.
  42. Bullous diseases of the oral mucosa. Rev Prat 2002, 15;52(4):385-8.
  43. Oral lichen planus and allergy to dental amalgam restorations. Arch Dermatol 2004, 140(12):1434-8.
  44. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103(Suppl S25):1-12.
  45. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 2007, 49(2):89-106.
  46. Drug reactions. XVI. Lichenoid drug eruptions. Br J Dermatol 1971, 85(6):604-7.
  47. Red and pigmented lesions. Br Dent J 2005, 199: 639–645.
  48. Disorders of pigmentation in the oral cavity. Clin Dermatol 2000,18:579-587.
  49. Discoloured tongue: a new cause? Br J Dermatol 2001, 144(6):1293-4.
  50. Fundamentals of operative dentistry. 2nd ed., Chicago, Quintessence Publishing Co., 2001:402.
  51. Esthetic dentistry, a clinical approach to techniques and materials. 2nd ed., Philadelphia, Mosby, 2001:247-249.
  52. Drug-induced disorders of teeth. J Dent Res 2005, 84(7):596-602.
  53. Minocycline-induced staining of the adult permanent dentition: a review of the literature and report of a case. Dent Update 1999, 26(4):160-162.
  54. Images in clinical medicine. Black hairy tongue. N Engl J Med 2006, 5;354(1):67.
  55. Black hairy tongue associated with olanzapine treatment: a case report. Mt Sinai J Med 2006, 73(6):891-4.
  56. Oral mucositis. Oral Dis 2006, 12(3):229-41.
  57. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006, 14(6):505-15.
  58. Buccodental health and oral mucositis. Clinical study in patients with hematological diseases. Med Oral Patol Oral Cir Bucal 2006, 11(6):E497-502.
  59. Drug-induced gingival overgrowth–a review. Biol Pharm Bull 2005, 28(10):1817-21.
  60. Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med 1992, 21(4):181-185.
  61. Keratinocyte growth factor receptor is up-regulated in cyclosporine-A induced gingival hyperplasia. J Dent Res 2002, 81(10):683-687.
  62. Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva: implications for gingival overgrowth. J Periodontol 1999, 70(3):294-300.
  63. The effects of human mast-cell products and of phenytoin on androgen 5alphareductase expression in human gingival fibroblasts. Arch Oral Biol 2001, 46(9):847-855.
  64. Oral problems and genetic aspects of individuals with epilepsy. Periodontol 2000,6:68-78.
  65. Nifedipine induces gingival epithelial hyperplasia in rats through inhibition of apoptosis. J Periodontol 2002, 73(8):861-867.
  66. On the relation of nitric oxide to nifedipine-induced gingival hyperplasia and impaired submandibular glands function in rats in vivo. Fund Clin Pharmacol 2005, 19(1):65-711–7.
  67. Inhibition by nifedipine of adherence- and activated macrophage-induced death of human gingival fibroblasts. Eur J Pharmacol 2001, 9;415(1):95-103.
  68. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 1993, 20(4):286-293.
  69. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontol 2001,27:131-8.
  70. Study on the correlations among disease activity index and salivary transforming growth factor-β1 and nitric oxide in ulcerative colitis patients. Ann NY Acad Sci 2007,1095:305-314.
  71. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-β1 in relation to disease activity in Crohn's disease patients. Ann NY Acad Sci 2006,1091:110-122.
  72. Alteration of cyclic nucleotides levels and oxidative stress in saliva of human subjects with periodontitis. J Contemp Dent Pract 2005,4:046-053.
  73. Oxidative stress and cholinesterase inhibition in saliva and plasma of rats following subchronic exposure to malathion. Comp Biochem Physiol C Toxicol Pharmacol 2004,137:29-34.
  74. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004, 49(11-12):1752-7.
  75. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res 2005, 36(4):376-381.
  76. Oral medicine -update for the dental practitioner: dry mouth and disorders of salivation. Br Dent J 2005, 199(7):423-7.
  77. Saliva: its role in health and disease. J Clin Gastroenterol 1988, 10(5):569-578.
  78. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 97(1):28-46.
  79. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. J Clin Gastroenterol 2005, 39(2):89-97.
  80. Drug-induced sialorrhea. Drugs Today (Barc) 2005, 41(6):411-8.
  81. The adverse drug reaction in the gastrointestinal tract: an overview. Int J Pharmacol 2005, 1(1):1-8.
  82. Effects of lithium on rat parotid and submandibulary gland functions. Gen Pharmacol 1995, 26(4):851-854.
  83. Protection by nitric oxide of morphine-induced inhibition of rat submandibular gland function. Pharmacol Res 2002, 45(2):87-92.
  84. Prevention by flumazenil of benzodiazepinessuppressed rat submandibular gland function. Ind J Pharmacol 2002,34:164-171.
  85. Inhibition of rat parotid and submandibular gland functions by ofloxacin, a fluoroquinolone antibiotic. Fundam Clin Pharmacol 2001; 15(5):307-311.
  86. Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function. Hum Exp Toxicol 2001, 20(1):28-33.
  87. L-arginine/nitric oxide pathway and interaction with lead acetate on rat submandibular gland function. Pharmacol Toxicol 2000, 87(5):198-203.
  88. Alteration by cadmium of rat submandibular gland secretory function and the role of the L-arginine/nitric oxide pathway. Pharmacol Res 2000, 42(6):591-597.
  89. Alteration of rat submandibulary gland secretion of protein, calcium and N-acetyl-beta-D-glucosaminidase activity by lead. Gen Pharmacol 1997, 29(4):675-680.
  90. Effects of cyclosporine A on the functions of submandibular and parotid glands of rats. Gen Pharmacol 1996, 27(5):887-890.
  91. On the relation of calcium channel blockers to rat parotid and submandibular glands function in vivo. Gen Pharmacol 1995, 26(3):619-622.
  92. Effects of vinca alkaloids on rat parotid and submandibular glands function in vivo. Gen Pharmacol 1995, 26(2):321-325.
  93. Effects of gentamicin on rat submandibulary gland functions. Gen Pharmacol 1994, 25(8):1719-1722.
  94. Lead intoxication in rats and its concentrations in blood and saliva. Toxic Subs Mech 1997,16:327-385.
  95. Alteration by rubidium of rat submandibular secretion of protein and N-acetyl-β-D-glucosaminidase. Toxic Subs Mech 1998,17:121-131.
  96. Alteration by lead acetate of rats submandibular gland morphology and ultrastructure. Toxic Subs Mech 1999,18:139-148.
  97. Facial swelling secondary to inhaled bronchodilator abuse: catecholamineinduced sialadenosis. Ann Allergy 1989, 62(4):289-293.
  98. Adverse drug reactions in the mouth. Clin Dermatol 2000, 18(5):525-532.
  99. Structural and functional changes by ciprofloxacin of rat submandibular gland. Hum Exp Toxicol 2003,22:177-181.
  100. Stimulation by theophylline and sildenafil of rat submandibular secretion of protein, epidermal growth factor and flow rate. Pharmacol Res 2003,48:445-449.
  101. Salivary gland swelling following naproxen therapy. Br J Dermatol 1995, 133(4):647-649.
  102. Sulfadiazine-induced sialadenitis. Ann Pharmacother 1997, 31(1):59-60.
  103. A suspected case of trimipramine-induced salivary adenitis. Drug Intell Clin Pharm 1982, 16(3):248-249.
  104. Managing the side effects of medications. J Dent Hyg 2000, 74(1):57-69.
  105. Fluoride metabolism and fluorosis. J Dent 2005, 33(3):177-86.
  106. Occurrence and management of dental fluorosis. Int Dent J 2001, 51(5):325-33.
  107. Prenatal anticonvulsant drug exposure: teratogenic effect on the dentition. J Craniofac Genet Dev Biol 1998, 18(3):129-37.
  108. Passive delayed eruption of the primary dentition secondary to Dilantin administration. Report of a case. Oral Surg Oral Med Oral Pathol 1981, 52(6):599-601.
  109. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 2007, [Epub ahead of print]
  110. Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 2007, 138(9):1218-20.
  111. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J 2007, 203(2):93-7.
  112. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005, 182(8):417-8.
  113. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007, 73(5):417-22.
  114. Four oral motor disorders: bruxism, dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions. Dent Clin North Am 2007, 51(1):225-43.
  115. Reversible ageusia associated with clopidogrel treatment. Neurol India 2006, 54(2):218-9.
  116. Objective assessment of terbinafine-induced taste loss. Laryngoscope 2005, 115(11):2035-7.
  117. Dysgeusia following a course of Zithromax: a case report. J N J Dent Assoc 2007, 78(2):24-7.
  118. Reversible dysgeusia attributed to azathioprine. Am J Gastroenterol 2007, 102(3):689.
  119. Adverse effects profile of sulfhydryl compounds in man. Am J Med 1986, 80(3):471-476.
  120. [Etiology, diagnostic and therapeutic management of taste disorders] Ther Umsch 2004, 61(5):302-7.
  121. Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Saf 1994, 11(5):318-77.
  122. Oral medicine--update for the dental practitioner: oral malodour. Br Dent J 2005, 199(8):498-500.
  123. Oral fungal infections. Dent Clin North Am 2005, 49(1):49-65.
  124. Alveolar osteitis: a review of its etiology, prevention, and treatment modalities. Gen Dent 2002, 50(5):457-63.
  125. Update on dry socket: a review of the literature. Med Oral Patol Oral Cir Bucal 2005, 10(1):81-5.
  126. Evaluation and management of angioedema of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2006, 14(3):170-5.
  127. Nonallergic angioedema: role of bradykinin. Allergy 2007, 62(8):842-56.
  128. Angioedema. J Am Acad Dermatol 2005, 53(3):373-88.
  129. Acquired angioedema secondary to hormone replacement therapy. Indian J Med Sci 2005, 59(10):451-4.
  130. Exposure to the oral side effects of medication in a community-based sample. Spec Care Dentist 2006, 26(3):116-20.
  131. Adverse drug interactions in dental practice. Professional and educational implications. J Am Dent Assoc 1999, 130(1):47-54.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.